InnoSlim® (Stimulant-Free Fat Burning)

Astragalus membranaceus / Panax notoginseng
Evidence Level
Moderate
1 Clinical Trial
3 Documented Benefits
3/5 Evidence Score

InnoSlim® (NuLiv Science) is a patented, stimulant-free fat loss and metabolic health ingredient — the same Astragalus membranaceus and Panax notoginseng combination as AstraGin® but with a different astragaloside/ginsenoside ratio optimized for glucose and fat metabolism rather than absorption enhancement. InnoSlim® reduces intestinal glucose absorption, activates AMPK in fat and muscle cells, and elevates adiponectin — producing fat loss, improved insulin sensitivity, and metabolic benefits without any stimulant activity.

Studied Dose 250 mg/day InnoSlim®; human study confirmed significant fat loss, glucose reduction, and adiponectin elevation at this dose; stimulant-free mechanism
Active Compound Astragalus membranaceus + Panax notoginseng extract (metabolism-optimized ginsenoside ratio) — InnoSlim® by NuLiv Science; different astragaloside/ginsenoside ratio vs. AstraGin®; standard dose 250 mg/day

Stimulant-free fat loss and body composition improvement

InnoSlim® reduces intestinal glucose absorption (by downregulating SGLT1 glucose transporter) and activates AMPK-driven fat oxidation in adipocytes — producing fat loss without any stimulant, thyroid, or adrenal activation. Human studies confirm significant reductions in body weight, body fat percentage, and waist circumference with InnoSlim® supplementation.

Adiponectin elevation and insulin sensitivity

InnoSlim® significantly elevates adiponectin — the key insulin-sensitizing hormone secreted by healthy adipose tissue. Higher adiponectin improves muscle glucose uptake, reduces liver fat, and shifts whole-body metabolism toward fat oxidation rather than fat storage — a fundamental metabolic improvement relevant to obesity, metabolic syndrome, and type 2 diabetes prevention.

Blood glucose management

By reducing SGLT1-mediated glucose absorption in the intestine and improving peripheral insulin sensitivity through adiponectin elevation, InnoSlim® produces clinically relevant reductions in fasting blood glucose and postprandial glucose excursions — effects relevant for both weight management and metabolic health applications.

1

SGLT1 downregulation and AMPK activation

InnoSlim®'s specific ginsenoside profile (Rb1-dominant) downregulates SGLT1 (sodium-glucose cotransporter 1) in intestinal epithelium — reducing dietary glucose absorption into circulation. The absorbed ginsenosides then activate AMPK (AMP-activated protein kinase) in muscle and adipose tissue, upregulating GLUT4 glucose transporter expression and shifting cellular metabolism toward fat oxidation. Concurrently, InnoSlim® stimulates adiponectin secretion from adipocytes through PPARγ activation — providing a systemic insulin-sensitizing hormone signal that amplifies the direct metabolic effects.

1
InnoSlim® Body Composition and Glucose Metabolism — Human Study
PubMed

Human clinical study of InnoSlim® (250 mg/day) effects on body weight, body fat, blood glucose, and adiponectin in overweight adults.

Overweight adults. Clinical assessment design.

InnoSlim® produced significant reductions in body weight, body fat percentage, and fasting blood glucose vs. control. Adiponectin levels significantly elevated. No stimulant-related side effects. Supports InnoSlim® as effective stimulant-free fat loss and metabolic health ingredient.

Common Potential side effects

Non-stimulant — no cardiovascular or CNS side effects
Generally well tolerated at 250 mg/day
Mild GI adjustment possible — take with food

Important Drug interactions

Antidiabetic medications — additive glucose-lowering; monitor blood glucose
SGLT2 inhibitors (gliflozins) — complementary mechanism; may have additive effect; monitor